151 related articles for article (PubMed ID: 9733145)
21. Androgen inactivation and steroid-converting enzyme expression in abdominal adipose tissue in men.
Blouin K; Richard C; Brochu G; Hould FS; Lebel S; Marceau S; Biron S; Luu-The V; Tchernof A
J Endocrinol; 2006 Dec; 191(3):637-49. PubMed ID: 17170221
[TBL] [Abstract][Full Text] [Related]
22. [Androgen receptor and 5 alpha-reductase activity in the epithelium and the stroma of human benign prostatic hyperplasia].
Oishi K; Okada K; Yoshida O; Romijn JC; Bolt de Vries J; Schröder FH
Hinyokika Kiyo; 1985 May; 31(5):785-90. PubMed ID: 2413745
[TBL] [Abstract][Full Text] [Related]
23. Androgen sensitivity of prostate epithelium is enhanced by postnatal androgen receptor inactivation.
Simanainen U; McNamara K; Gao YR; Handelsman DJ
Am J Physiol Endocrinol Metab; 2009 Jun; 296(6):E1335-43. PubMed ID: 19366880
[TBL] [Abstract][Full Text] [Related]
24. Immunoreactive EGF in human benign prostatic hyperplasia: relationships with androgen and estrogen receptors.
Lubrano C; Sciarra F; Spera G; Petrangeli E; Toscano V; Rombola N; Palleschi F; Palma E; Di Silverio F
J Steroid Biochem Mol Biol; 1992 Mar; 41(3-8):683-7. PubMed ID: 1373303
[TBL] [Abstract][Full Text] [Related]
25. Effect of aging on endogenous level of 5 alpha-dihydrotestosterone, testosterone, estradiol, and estrone in epithelium and stroma of normal and hyperplastic human prostate.
Krieg M; Nass R; Tunn S
J Clin Endocrinol Metab; 1993 Aug; 77(2):375-81. PubMed ID: 7688377
[TBL] [Abstract][Full Text] [Related]
26. Androgen receptor content of normal and hyperplastic human prostate.
Trachtenberg J; Bujnovszky P; Walsh PC
J Clin Endocrinol Metab; 1982 Jan; 54(1):17-21. PubMed ID: 6172440
[TBL] [Abstract][Full Text] [Related]
27. Apoptosis and hormonal milieu in ductal system of normal prostate and benign prostatic hyperplasia.
Xia SJ; Xu CX; Tang XD; Wang WZ; Du DL
Asian J Androl; 2001 Jun; 3(2):131-4. PubMed ID: 11404798
[TBL] [Abstract][Full Text] [Related]
28. Endogenous steroid levels in the human prostate from birth to old age: a comparison of normal and diseased tissues.
Hammond GL
J Endocrinol; 1978 Jul; 78(1):7-19. PubMed ID: 79632
[TBL] [Abstract][Full Text] [Related]
29. Concentration of the endogenous antiandrogen epitestosterone and androgenic C19-steroids in hyperplastic prostatic tissue.
Hill M; Hampl R; Petrík R; Stárka L
Prostate; 1996 Jun; 28(6):347-51. PubMed ID: 8650070
[TBL] [Abstract][Full Text] [Related]
30. Effect of dutasteride on intraprostatic androgen levels in men with benign prostatic hyperplasia or prostate cancer.
Rittmaster R; Hahn RG; Ray P; Shannon JB; Wurzel R
Urology; 2008 Oct; 72(4):808-12. PubMed ID: 18718641
[TBL] [Abstract][Full Text] [Related]
31. Fat boosts, while androgen receptor activation counteracts, BPH-associated prostate inflammation.
Vignozzi L; Gacci M; Cellai I; Santi R; Corona G; Morelli A; Rastrelli G; Comeglio P; Sebastanelli A; Maneschi E; Nesi G; De Nunzio C; Tubaro A; Mannucci E; Carini M; Maggi M
Prostate; 2013 Jun; 73(8):789-800. PubMed ID: 23620238
[TBL] [Abstract][Full Text] [Related]
32. Androgen concentration in blacks with benign and malignant prostatic disease.
Osegbe DN; Ogunlewe JO
J Urol; 1988 Jul; 140(1):160-4. PubMed ID: 2454327
[TBL] [Abstract][Full Text] [Related]
33. Sex steroids and epidermal growth factor in benign prostatic hyperplasia (BPH).
Sciarra F
Ann N Y Acad Sci; 1995 Jun; 761():66-78. PubMed ID: 7542859
[TBL] [Abstract][Full Text] [Related]
34. Androgen and prostatic stroma.
Niu YJ; Ma TX; Zhang J; Xu Y; Han RF; Sun G
Asian J Androl; 2003 Mar; 5(1):19-26. PubMed ID: 12646998
[TBL] [Abstract][Full Text] [Related]
35. Baldness, benign prostate hyperplasia, prostate cancer and androgen levels.
Faydaci G; Bilal E; Necmettin P; Fatih T; Asuman O; Uğur K
Aging Male; 2008 Dec; 11(4):189-92. PubMed ID: 19172550
[TBL] [Abstract][Full Text] [Related]
36. Androgens and androgen-receptors in prostate tissue from patients with benign prostatic hyperplasia: effects of cyproterone acetate.
de Jong FH; Reuvers PJ; Bolt-de Vries J; Mulder E; Blom JH; Schroeder FH
J Steroid Biochem Mol Biol; 1992 Mar; 42(1):49-55. PubMed ID: 1373073
[TBL] [Abstract][Full Text] [Related]
37. Impaired dihydrotestosterone catabolism in human prostate cancer: critical role of AKR1C2 as a pre-receptor regulator of androgen receptor signaling.
Ji Q; Chang L; Stanczyk FZ; Ookhtens M; Sherrod A; Stolz A
Cancer Res; 2007 Feb; 67(3):1361-9. PubMed ID: 17283174
[TBL] [Abstract][Full Text] [Related]
38. Cytopathological changes in early stages of benign prostatic hyperplasia upon exposure to sustained delivery of androgens.
Pollan MC; Benghuzzi HA; Tucci M
Biomed Sci Instrum; 2002; 38():15-20. PubMed ID: 12085593
[TBL] [Abstract][Full Text] [Related]
39. Can the intraprostatic concentration of epidermal growth factor influence the variance of serum prostate specific antigen levels in patients with benign prostatic hyperplasia?
Di Silverio F; Sciarra A; Monti S; Casale P; Seccareccia F
J Urol; 1999 Jan; 161(1):128-32. PubMed ID: 10037384
[TBL] [Abstract][Full Text] [Related]
40. Effects of steroids on oxytocin secretion by the human prostate in vitro.
Assinder SJ; Nicholson HD
Int J Androl; 2004 Feb; 27(1):12-8. PubMed ID: 14718041
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
